UB Paderborn / Katalog / Suche / in CDI

Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer

Scientific reports, 2021-12, Vol.11 (1), p.24015-24015, Article 24015

2021

Link zum Volltext

Verfügbarkeit prüfen

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV

Annals of oncology, 2016-02, Vol.27 (2), p.267-274

2016

Link zum Volltext

Verfügbarkeit prüfen

Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer

European journal of cancer (1990), 2011-12, Vol.47 (18), p.2681-2690

2011

Link zum Volltext

Verfügbarkeit prüfen

Integrated management of mother and child health in the region of Monastir /Prise en charge integree de la sante de la mere et de l'enfant dans la region de Monastir

Eastern Mediterranean health journal, 2014-08, Vol.20 (8), p.483

2014

Link zum Volltext

Verfügbarkeit prüfen

Prise en charge intégrée de la santé de la mère et de l'enfant dans la région de Monastir (Tunisie)/Integrated management of mother and child health in the region of Monastir (Tunisia)

Eastern Mediterranean health journal, 2014-08, Vol.20 (8), p.483

2014

Link zum Volltext

Verfügbarkeit prüfen

Integrated management of mother and child health in the region of Monastir (Tunisia)

Eastern Mediterranean health journal, 2014-08, Vol.20 (8), p.483-490

2014

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

Critical reviews in oncology/hematology, 2008-09, Vol.67 (3), p.255-262

2008

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

Medical oncology (Northwood, London, England), 2011-12, Vol.28 (Suppl 1), p.253-258

2011

Link zum Volltext

Verfügbarkeit prüfen

Undetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Annals of oncology, 2019-10, Vol.30, p.v223-v224

2019

Link zum Volltext

Verfügbarkeit prüfen

592P - Undetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Annals of oncology, 2019-10, Vol.30, p.v223-v224

2019

Link zum Volltext

Verfügbarkeit prüfen

Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronoIFLO4) combination at home

Annals of oncology, 2017-09, Vol.28, p.v549-v550

2017

Link zum Volltext

Verfügbarkeit prüfen

1038 OBJECTIVE CORRELATES OF SLEEP COMPLAINT IN CANCER PATIENTS ON CHEMOTHERAPY TELE-MONITORED AT HOME: NIGHT-BY-NIGHT ANALYSIS

Sleep (New York, N.Y.), 2017-04, Vol.40 (suppl_1), p.A386-A386

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3529-3529

2005

Link zum Volltext

Verfügbarkeit prüfen

Integrated management of mother and child health in the region of Monastir (Tunisia)/Prise en charge integree de la sante de la mere et de l'enfant dans la region de Monastir

Eastern Mediterranean health journal, 2014-08, Vol.20 (8), p.483

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial

Annals of oncology, 2012-09, Vol.23, p.ix194

2012

Link zum Volltext

Verfügbarkeit prüfen

568P - Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial

Annals of oncology, 2012-09, Vol.23, p.ix194-ix194

2012

Link zum Volltext

Verfügbarkeit prüfen

Detection of Health-Related Warning Signals Through Daily Telemonitoring of Cancer Patients on Multidrug Chemotherapy at Home (European Project Incasa)

Annals of oncology, 2014-09, Vol.25, p.iv534

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-pharmacodynamic analysis of hepatic artery infusion of three-drug chronomodulated chemotherapy and intravenous cetuximab in patients with liver metastases from colorectal cancer registered in OPTILIV, a European multicenter phase II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e14134-e14134

2011

Link zum Volltext

Verfügbarkeit prüfen

592PUndetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV—A European multicenter phase II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e14102-e14102

2011

Link zum Volltext

Verfügbarkeit prüfen

Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS198-TPS198

2010

Link zum Volltext

Verfügbarkeit prüfen

Relevance of a medicosurgical strategy combining cetuximab and chronomodulated (Chrono) chemotherapy (chemo) with metastases resection as 3rd line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14505-14505

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of cetuximab (C) given with a simplified, every other week (q2w), schedule in patients (pts) with advanced colorectal cancer (aCRC): A multicenter, retrospective study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15118-15118

2008

Link zum Volltext

Verfügbarkeit prüfen

Medico-pharmaceutical approach to reduce costs of infusion-related reactions (IRR) associated with cetuximab at Paul Brousse hospital

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20748-20748

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV

Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer

Integrated management of mother and child health in the region of Monastir /Prise en charge integree de la sante de la mere et de l'enfant dans la region de Monastir

Prise en charge intégrée de la santé de la mère et de l'enfant dans la région de Monastir (Tunisie)/Integrated management of mother and child health in the region of Monastir (Tunisia)

Integrated management of mother and child health in the region of Monastir (Tunisia)

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

Undetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

592P - Undetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronoIFLO4) combination at home

1038 OBJECTIVE CORRELATES OF SLEEP COMPLAINT IN CANCER PATIENTS ON CHEMOTHERAPY TELE-MONITORED AT HOME: NIGHT-BY-NIGHT ANALYSIS

Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM)

Integrated management of mother and child health in the region of Monastir (Tunisia)/Prise en charge integree de la sante de la mere et de l'enfant dans la region de Monastir

Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial

568P - Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial

Detection of Health-Related Warning Signals Through Daily Telemonitoring of Cancer Patients on Multidrug Chemotherapy at Home (European Project Incasa)

Pharmacokinetic-pharmacodynamic analysis of hepatic artery infusion of three-drug chronomodulated chemotherapy and intravenous cetuximab in patients with liver metastases from colorectal cancer registered in OPTILIV, a European multicenter phase II trial

592PUndetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial

Relevance of a medicosurgical strategy combining cetuximab and chronomodulated (Chrono) chemotherapy (chemo) with metastases resection as 3rd line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Efficacy and safety of cetuximab (C) given with a simplified, every other week (q2w), schedule in patients (pts) with advanced colorectal cancer (aCRC): A multicenter, retrospective study

Medico-pharmaceutical approach to reduce costs of infusion-related reactions (IRR) associated with cetuximab at Paul Brousse hospital

Suchergebnisse filtern